References
- Kisilevsky R, Axelrad M, Corbett W, Brunet S, Scott F. The role of inflammatory cells in the pathogenesis of amyloidosis. Lab Invest 1977; 37: 544–553
- Sipe J D, McAdam K P, Torain B F, Pollock P S. Isolation and structural properties of murine SAA-the acute phase serum precursor of amyloid AA. Immunol Commun 1977; 6: 1–12
- Kisilevsky R. Anti-amyloid drugs: Potential in the treatment of disease associated with aging. Drugs and Aging 1996; 8: 75–83
- Benson M D, Kleiner E. Synthesis and secretion of serum amyloid protein A (SAA) by hepatocytes in mice treated with casein. J Immunol 1980; 124: 495–499
- Sipe J D, McAdam K PWJ, Uchino F. Biochemical evidence for the biphasic development of experimental amyloidosis. Lab Invest 1978; 38: 110–114
- McAdam K PWJ, Sipe J D. Murine model for human secondary amyloidosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. J Exp Med 1976; 144: 1121–1127
- Tape C, Tan R, Nesheim M, Kisilevsky R. Direct evidence for circulating apoSAA as the precursor of tissue AA amyloid deposits. Scand J Immunol 1988; 28: 317–324
- Shiroo M, Kawahara E, Nakanishi I, Migita S. Specific deposition of serum amyloid A protein 2 in the mouse. Scand J Immunol 1987; 26: 709–716
- Sipe J. Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid Int J Exp Clin Invest 1999; 6: 67–70
- de Beer M C, de Beer F C, McCubbin W D, Kay C M, Kindy M S. Structural prerequisites for serum amyloid A fibril formation. J Biol Chem 1993; 268: 20606–20612
- Patel H, Bramall J, Waters H, De Beer M C, Woo P. Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis. Biochem J 1996; 318: 1041–1049
- Sipe J D, Carreras I, Gonnerman W A, Cathcart E S, de Beer M C, de Beer F C. Characterization of the inbred CE/J mouse strain as amyloid resistant. Am J Pathol 1993; 143: 1480–1485
- Kindy M S, King A R, Yu J, Gerardot C, Whitley J, de Beer F C. Adenoviral expression of murine serum amyloid A proteins to study amyloid fibrillogenesis. Biochem J 1998; 332: 721–728
- Webb N R, de Beer M C, van der Westhuyzen D R, Kindy M S, Banka C L, Tsukamoto K, Rader D L, de Beer F C. Adenoviral vector-mediated overexpression of serum amyloid A in apoA-I-deficient mice. J Lipid Res 1997; 38: 1583–1590
- Kindy M S, de Beer F C. A mouse model for serum amyloid A amyloidosis. Methods in Enzymology 1999, in press
- Come J H, Fraser P E, Lansbury P T. A kinetic model for amyloid formation in prion diseases - importance of seeding. Proc Natl Acad Sci 1993; 90: 5959–5963
- Green C J. Amyloidosis as an incidental finding in rats on experiment. Lab Anim 1974; 8: 99–101
- Meek R L, Benditt E P. Rat tissues express serum amyloid A protein-related mRNAs. Proc Natl Acad Sci 1989; 86: 1890–1894
- Baltz M L, Rowe I F, Caspi D, Turnell W G, Pepys M B. Acute-phase high density lipoprotein in the rat does not contain serum amyloid A protein. Biochem J 1987; 242: 301–303
- Benditt E P, Eriksen N, Hanson R H. Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci USA 1979; 76: 4092–4096
- Kindy M S, King A R, Perry G, de Beer M C, de Beer F C. Association of apolipoprotein E with murine amyloid A protein amyloid. Lab Invest 1995; 73: 469–475
- Feinberg A P, Vogelstein B. “A technique for ra-diolabeling DNA restriction endonuclease fragments to high specific activity”. Anal Biochem 1984; 137: 266–267
- Kindy M S, Rader D J. Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice. Am J Pathol 1998; 152: 1387–1395
- de Beer M C, Yuan T, Kindy M S, Asztalos B F, Roheim P S, de Beer F C. Characterization of constitutive human serum amyloid A protein (SAA4) as an apolipoprotein. J Lipid Res 1995; 36: 526–534
- Lasser N L, Roheim P S, Edelstein D, Eder H A. Serum lipoproteins of normal and cholesterol-fed rats. J Lipid Res 1973; 14: 1–8
- Pras M, Shubert M, Zucker-Franklin D, Rimon A, Franklin E. The characterization of soluble amyloid prepared in water. J Clin Invest 1968; 47: 924–933
- Engelhardt J F, Ye X, Doranz B, Wilson J M. Ablation of E2a in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci 1994; 91: 6196–6200
- Axelrad M A, Kisilevsky R, Willmer J, Chen S J, Skinner M. Further characterization of amyloid-enhancing factor. Lab Invest 1982; 47: 139–146
- Puchtler H, Sweat F. Congo red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 1965; 13: 693–694
- Sipe J, Rokita H, Shirahama T, Cohen A, Koj A. Analysis of SAA gene expression in rat and mouse during acute phase inflammation and accelerated amyloidogenesis. Protides Biol Fluids 1986; 34: 331–334
- Kozarsky K F, McKinley D R, Austin L L, Raper S E, Stratford-Perricaudet L D, Wilson J M. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695–702
- Meek R L, Benditt E P. Amyloid A gene family expression in different mouse tissues. J Exp Med 1986; 164: 2006–2017
- Meek R L, Hoffman J S, Benditt E P. Amyloidogenesis. One serum amyloid A isotype is selectively removed from the circulation. J Exp Med 1986; 163: 499–510